Moody's rates BioScrip's new debt; Caa2 CFR affirmed
Rating Action: Moody's rates BioScrip's new debt; Caa2 CFR affirmed. Global Credit Research- 01 Aug 2017. New York, August 01, 2017-- Moody's Investors Service affirmed BioScrip, Inc's Caa2 Corporate Family Rating and Caa3 senior unsecured notes rating and upgraded the Probability of Default Rating to Caa1-PD from Caa2-PD following the refinancing.BioScrip is a provider of infusion solutions. The company partners with physicians, hospital systems, skilled nursing facilities, and healthcare payors to provide patients access to post-acute care services. Whether in the home, physician office, ambulatory infusion center, nursing facility or other alternate sites of care, the company provides products, services and clinical management programs to improve the care of individuals with health conditions such as gastrointestinal abnormalities, infectious diseases, cancer, multiple sclerosis, organ and blood cell transplants, bleeding disorders, immune deficiencies and heart failure. As of Dec 31 2017, the company had a total of 66 service locations in 27 states.
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.